Eli Lilly and Co. (NYSE:LLY) stock is trading higher after the weight loss drug giant released better-than-expected first quarter 2026 earnings and raised fiscal 2026 guidance.
Earnings Overview Shows Strong Growth
Eli Lilly reported first-quarter adjusted earnings of $8.55 per share, beating the consensus of $6.66.
The company’s sales reached $19.79 billion, beating the consensus of $17.62 billion.
Sales jumped 56% year over year, driven by a 65% increase in volume, partially offset by a 13% decrease due to lower realized prices.
Key Products revenue grew to $13.4 billion in the quarter, led by Mounjaro and Zepbound.
Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 160%.
data-variant=”card”
data-news-mode=”manual”
>
Read Also:
Eli Lilly, Profluent Target Complex Genetic Diseases With AI-Driven Custom DNA Tools